Tobira Therapeutics Inc. (NASDAQ:TBRA)’s share price shot up 3.2% during mid-day trading on Thursday . The stock traded as high as $4.82 and last traded at $4.77, with a volume of 136,240 shares traded. The stock had previously closed at $4.62.

TBRA has been the topic of a number of recent analyst reports. Cowen and Company reiterated a “buy” rating and issued a $11.00 price objective on shares of Tobira Therapeutics in a research report on Wednesday, August 10th. Cantor Fitzgerald initiated coverage on Tobira Therapeutics in a research report on Wednesday, July 6th. They issued a “buy” rating and a $27.00 price objective on the stock. Zacks Investment Research lowered Tobira Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th. HC Wainwright reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Tuesday, May 10th. Finally, Leerink Swann reiterated a “buy” rating on shares of Tobira Therapeutics in a research report on Monday, May 2nd. Five analysts have rated the stock with a buy rating, Tobira Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $16.75.

The company’s 50-day moving average price is $7.75 and its 200-day moving average price is $8.32. The stock’s market capitalization is $89.78 million.

Tobira Therapeutics (NASDAQ:TBRA) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.08. The company earned $1.06 million during the quarter. On average, equities analysts expect that Tobira Therapeutics Inc. will post ($2.65) earnings per share for the current year.

In related news, major shareholder A/S Novo sold 59,067 shares of the business’s stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $12.02, for a total value of $709,985.34. Following the sale, the insider now directly owns 1,914,541 shares in the company, valued at $23,012,782.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP acquired a new position in shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned about 0.57% of Tobira Therapeutics as of its most recent filing with the SEC.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.